Simulating therapeutics using multiscale models of the VEGF receptor system in cancer

Feilim Mac Gabhann, Marianne O. Stefanini, Aleksander S Popel

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In recent years, Judah Folkman's vision of anticancer therapeutics based on inhibiting angiogenesis pathways has begun to be realized. In particular, antibodies sequestering VEGF, and small molecule tyrosine kinase inhibitors targeting VEGF receptors, are now approved for various cancers, alone or in combination with other therapies. More are in the development pipeline, with similar or distinct mechanisms of action. The VEGF system is complex, involving multiple ligands and receptors, along with transport throughout the body via the bloodstream. Predicting outcomes of perturbing this system, either by a single agent or combinations, can be aided by in silico models. Here we discuss the ways in which the above drugs target the VEGF pathway in cancer, and describe the development and implementation of multiscale mathematical models to simulate the action of these drugs in order to predict and compare their likely efficacy for various types of tumors.

Original languageEnglish (US)
Title of host publicationModeling Tumor Vasculature: Molecular, Cellular, and Tissue Level Aspects and Implications
PublisherSpringer New York
Pages37-53
Number of pages17
Volume9781461400523
ISBN (Print)9781461400523, 1461400511, 9781461400516
DOIs
StatePublished - Nov 1 2012

Fingerprint

Vascular Endothelial Growth Factor Receptor
Vascular Endothelial Growth Factor A
Neoplasms
Pharmaceutical Preparations
Computer Simulation
Protein-Tyrosine Kinases
Theoretical Models
Therapeutics
Ligands
Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mac Gabhann, F., Stefanini, M. O., & Popel, A. S. (2012). Simulating therapeutics using multiscale models of the VEGF receptor system in cancer. In Modeling Tumor Vasculature: Molecular, Cellular, and Tissue Level Aspects and Implications (Vol. 9781461400523, pp. 37-53). Springer New York. https://doi.org/10.1007/978-1-4614-0052-3_2

Simulating therapeutics using multiscale models of the VEGF receptor system in cancer. / Mac Gabhann, Feilim; Stefanini, Marianne O.; Popel, Aleksander S.

Modeling Tumor Vasculature: Molecular, Cellular, and Tissue Level Aspects and Implications. Vol. 9781461400523 Springer New York, 2012. p. 37-53.

Research output: Chapter in Book/Report/Conference proceedingChapter

Mac Gabhann, F, Stefanini, MO & Popel, AS 2012, Simulating therapeutics using multiscale models of the VEGF receptor system in cancer. in Modeling Tumor Vasculature: Molecular, Cellular, and Tissue Level Aspects and Implications. vol. 9781461400523, Springer New York, pp. 37-53. https://doi.org/10.1007/978-1-4614-0052-3_2
Mac Gabhann F, Stefanini MO, Popel AS. Simulating therapeutics using multiscale models of the VEGF receptor system in cancer. In Modeling Tumor Vasculature: Molecular, Cellular, and Tissue Level Aspects and Implications. Vol. 9781461400523. Springer New York. 2012. p. 37-53 https://doi.org/10.1007/978-1-4614-0052-3_2
Mac Gabhann, Feilim ; Stefanini, Marianne O. ; Popel, Aleksander S. / Simulating therapeutics using multiscale models of the VEGF receptor system in cancer. Modeling Tumor Vasculature: Molecular, Cellular, and Tissue Level Aspects and Implications. Vol. 9781461400523 Springer New York, 2012. pp. 37-53
@inbook{15cbc5a981494342ad8cbe31cdbd5ffa,
title = "Simulating therapeutics using multiscale models of the VEGF receptor system in cancer",
abstract = "In recent years, Judah Folkman's vision of anticancer therapeutics based on inhibiting angiogenesis pathways has begun to be realized. In particular, antibodies sequestering VEGF, and small molecule tyrosine kinase inhibitors targeting VEGF receptors, are now approved for various cancers, alone or in combination with other therapies. More are in the development pipeline, with similar or distinct mechanisms of action. The VEGF system is complex, involving multiple ligands and receptors, along with transport throughout the body via the bloodstream. Predicting outcomes of perturbing this system, either by a single agent or combinations, can be aided by in silico models. Here we discuss the ways in which the above drugs target the VEGF pathway in cancer, and describe the development and implementation of multiscale mathematical models to simulate the action of these drugs in order to predict and compare their likely efficacy for various types of tumors.",
author = "{Mac Gabhann}, Feilim and Stefanini, {Marianne O.} and Popel, {Aleksander S}",
year = "2012",
month = "11",
day = "1",
doi = "10.1007/978-1-4614-0052-3_2",
language = "English (US)",
isbn = "9781461400523",
volume = "9781461400523",
pages = "37--53",
booktitle = "Modeling Tumor Vasculature: Molecular, Cellular, and Tissue Level Aspects and Implications",
publisher = "Springer New York",

}

TY - CHAP

T1 - Simulating therapeutics using multiscale models of the VEGF receptor system in cancer

AU - Mac Gabhann, Feilim

AU - Stefanini, Marianne O.

AU - Popel, Aleksander S

PY - 2012/11/1

Y1 - 2012/11/1

N2 - In recent years, Judah Folkman's vision of anticancer therapeutics based on inhibiting angiogenesis pathways has begun to be realized. In particular, antibodies sequestering VEGF, and small molecule tyrosine kinase inhibitors targeting VEGF receptors, are now approved for various cancers, alone or in combination with other therapies. More are in the development pipeline, with similar or distinct mechanisms of action. The VEGF system is complex, involving multiple ligands and receptors, along with transport throughout the body via the bloodstream. Predicting outcomes of perturbing this system, either by a single agent or combinations, can be aided by in silico models. Here we discuss the ways in which the above drugs target the VEGF pathway in cancer, and describe the development and implementation of multiscale mathematical models to simulate the action of these drugs in order to predict and compare their likely efficacy for various types of tumors.

AB - In recent years, Judah Folkman's vision of anticancer therapeutics based on inhibiting angiogenesis pathways has begun to be realized. In particular, antibodies sequestering VEGF, and small molecule tyrosine kinase inhibitors targeting VEGF receptors, are now approved for various cancers, alone or in combination with other therapies. More are in the development pipeline, with similar or distinct mechanisms of action. The VEGF system is complex, involving multiple ligands and receptors, along with transport throughout the body via the bloodstream. Predicting outcomes of perturbing this system, either by a single agent or combinations, can be aided by in silico models. Here we discuss the ways in which the above drugs target the VEGF pathway in cancer, and describe the development and implementation of multiscale mathematical models to simulate the action of these drugs in order to predict and compare their likely efficacy for various types of tumors.

UR - http://www.scopus.com/inward/record.url?scp=84949176866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949176866&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-0052-3_2

DO - 10.1007/978-1-4614-0052-3_2

M3 - Chapter

AN - SCOPUS:84949176866

SN - 9781461400523

SN - 1461400511

SN - 9781461400516

VL - 9781461400523

SP - 37

EP - 53

BT - Modeling Tumor Vasculature: Molecular, Cellular, and Tissue Level Aspects and Implications

PB - Springer New York

ER -